Yejing Zhu
Overview
Explore the profile of Yejing Zhu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xu F, Zhao S, Zhu Y, Zhu J, Kong L, Li H, et al.
Life Metab
. 2025 Jan;
3(6):loae026.
PMID: 39873005
Metabolic dysfunction-associated steatohepatitis (MASH) is one of the most common chronic liver diseases and is mainly caused by metabolic disorders and systemic inflammatory responses. Recent studies have indicated that the...
2.
Zhou H, Tang Y, Zhang Y, Zhu Y, Dong S
Medicine (Baltimore)
. 2024 Jan;
103(1):e36618.
PMID: 38181275
Rationale: Intracranial aneurysm (IA) is defined as a localized dilation of cerebral arteries. With the continuous development of modern medical technology, surgery is still one of the main treatment methods....
3.
Dong S, Zhu Y, Zhang F, Zhao Y, Zhou H
Medicine (Baltimore)
. 2024 Jan;
103(1):e36619.
PMID: 38181249
Rationale: Acute promyelocytic leukaemia (APL) is a rare subtype of acute myelogenous leukaemia. With advances in treatment regimens, namely, introduction of all-trans-retinoicacid, outcomes have drastically improved, its side effects should...
4.
Ma S, Tian Z, Liu L, Zhu J, Wang J, Zhao S, et al.
Small
. 2023 Nov;
20(16):e2308638.
PMID: 38018295
Immunotherapy is a promising cancer therapeutic strategy. However, the "cold" tumor immune microenvironment (TIME), characterized by insufficient immune cell infiltration and immunosuppressive status, limits the efficacy of immunotherapy. Tumor vascular...
5.
Zhu Y, Chi J, Cai S, Liu S, Yuan J, Xu H, et al.
Int J Med Sci
. 2023 Oct;
20(12):1570-1583.
PMID: 37859698
The aim of this study was to investigate whether calcium-sensing receptor (CaSR) was involved in HRF-mediated exacerbation of MI/R injury through NLRP3 inflammasome activation and pyroptosis. , a rat MI/R...
6.
Bai T, Wang E, Zhao S, Han D, Zhao Y, Chen H, et al.
Front Oncol
. 2023 Jul;
13:1170923.
PMID: 37434986
Background: Advanced hepatocellular carcinoma (HCC) is characterized as symptomatic tumors [performance status (PS) score of 1-2], vascular invasion and extrahepatic spread, but patients with PS1 alone may be eliminated from...
7.
Lei S, Du X, Tan K, He X, Zhu Y, Zhao S, et al.
Exp Ther Med
. 2023 Jun;
26(1):314.
PMID: 37273753
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. It has been reported that cysteine rich protein 1 (CRP-1) is dysregulated in several types of human cancer; however,...
8.
Zhu Y, Wang E, Zhao S, Han D, Zhao Y, Chen H, et al.
Front Oncol
. 2023 Feb;
12:983554.
PMID: 36776366
Background: Hepatoma arterial-embolization prognostic (HAP) series scores have been proposed for prognostic prediction in patients with unresectable hepatocellular carcinoma (uHCC) undergoing transarterial chemoembolization (TACE). However, their prognostic value in TACE...
9.
Zhao J, Tian Z, Zhao S, Feng D, Guo Z, Wen L, et al.
Adv Sci (Weinh)
. 2022 Dec;
10(4):e2204808.
PMID: 36479819
Lactate, a characteristic metabolite of the tumor microenvironment (TME), drives immunosuppression and promotes tumor progression. Material-engineered strategies for intratumoral lactate modulations demonstrate their promise for tumor immunotherapy. However, understanding of...
10.
Zhu J, Han T, Zhao S, Zhu Y, Ma S, Xu F, et al.
Front Oncol
. 2022 Jul;
12:933210.
PMID: 35875102
Necroptosis is a programmed form of necrotic cell death in regulating cancer ontogenesis, progression, and tumor microenvironment (TME) and could drive tumor-infiltrating cells to release pro-inflammatory cytokines, incurring strong immune...